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A reliable, accurate, noninvasive method for identifying
patients with GERD in the primary care setting is needed.
A population-screening instrument may assist managed
care organizations and clinicians to identify candidates
for disease management, or quality improvement pro-
grams. OBJECTIVE: To develop and validate a GERD
screening instrument. METHODS: A screening instru-
ment containing 10 questions was developed based on lit-
erature review and expert opinion. Categorical and con-
tinuous scoring methods with and without medication
use were identified a priori. Using telephone interview in
a medical group, we identified and enrolled 100 subjects
with a history of GERD-like symptoms and 100 controls.
Each subject completed the screening instrument, a vali-
dated gastrointestinal symptom questionnaire (DHSI),
and was evaluated independently by 2 gastroenterologists
using a structured format. The gold standard was defined
as patients who required an intervention and who had
physician agreement that their symptoms were consistent
with GERD. RESULTS: 70 subjects were classified as
GERD using the gold standard (kappa  0.79). Using a
continuous measure of GERD symptoms, including fre-
quency, severity, and type of medication use as the scor-
ing method (total score range 0–29), an area under the
receiver operator characteristic curve (ROC) of 0.89
(95% CI 0.84–0.94) was observed. Using a cutoff of 9
points, this measure is 83% sensitive and 82% specific.
Using a cutoff of 12 points, this measure is 65% sensi-
tive and 92% specific. Compared to the gold standard,
the DHSI GERD subscale has a ROC of 0.89 (95% CI
0.84–0.94). The screening instrument was highly corre-
lated with the DHSI GERD subscale, r  0.74 (95% CI
0.67–0.80; P  0.0001). CONCLUSIONS: The screen-
ing instrument appears to have construct, convergent and
predictive validity. It is shorter than existing validated in-
struments, practical and easily administered. This may
serve as a valuable case-finding instrument in primary
care and managed care organizations.
 
D2
 
COST UTILITY OF DOCETAXEL VS 
VINORELBINE OR PACLITAXEL IN ADVANCED 
BREAST CANCER
 
Brown R
 
1
 
, Hutton J
 
2
 
1
 
MEDTAP International Inc., Bethesda, MD, USA; 
 
2
 
MEDTAP 
International Inc., London, UK
 
There are three licensed alternatives for managing ad-
vanced breast cancer (ABC) patients in the UK, but they
have not been directly compared in clinical studies. OB-
JECTIVE: To capture the costs and quality of life (QoL)
related outcomes for ABC patients managed with doce-
taxel (DOC) in comparison to vinorelbine (VIN) and pac-
litaxel (PAC). METHODS: An updated version of the
Hutton et al. (Pharmacoeconomics 9 Suppl 2, 1996)
model was used to simulate the experiences (associated
costs and outcomes) of patients undergoing treatment for
ABC, from the onset of salvage chemotherapy to death.
Published clinical trials were used to establish response
rate, time to progression, median survival, rate of grade
four febrile neutropenia, and toxicity rate related to che-
motherapeutic agent. QoL utility scores were obtained
from oncology nurses. Costs were taken from published
sources and reflect the UK National Health Service and
were discounted at 6%. RESULTS: The average patient
costs were £4268 for VIN, £7817 for DOC and £7645
for PAC. The estimated Quality Adjusted Life Year (QALY)
values were 0.48 for VIN, 0.73 for DOC and 0.65 for
PAC; an additional 91 days of good quality life for DOC
versus VIN and an additional 29 days of good quality life
versus PAC. The incremental cost per QALY for DOC
was £14,500 compared with VIN and £1,990 compared
with PAC. Various sensitivity analyses were undertaken
and did not greatly change the findings. The cost-effec-
tiveness ratios are within the range of generally accept-
able technologies. CONCLUSION: Patients managed
with DOC have improved QoL in comparison to these
alternative chemotherapies and a longer median survival.
 
D3
 
A PHARMACOECONOMIC MODEL TO ASSESS 
THE COST-EFFECTIVENESS OF 
TROVAFLOXACIN COMPARED TO CEFTAZIDIME 
FOR NOSOCOMIAL PNEUMONIA IN A PUBLIC 
HOSPITAL SETTING IN HONG KONG
Lee KKC
 
1
 
, You JHS
 
1
 
, Ho SSS
 
1
 
, Chan TYK
 
2
 
1
 
Departments of Pharmacy, The Chinese University of Hong 
Kong, Shatin, Hong Kong, China; 
 
2
 
Medicine & Therapeutics, 
The Chinese University of Hong Kong, Shatin,
Hong Kong, China
